So­sei and Ver­i­ly part­ner on GPCRs; Ob­sE­va touts PhI­II da­ta in en­dometrio­sis pain

So­sei Hep­tares is team­ing up with a big-name part­ner: Al­pha­bet’s Ver­i­ly.

No fi­nan­cials were dis­closed, but the pair will aim to use Ver­i­ly’s im­mune pro­fil­ing and So­sei Hep­tares’ GPCR drug de­sign ca­pa­bil­i­ties to de­vel­op a va­ri­ety of new ther­a­peu­tics. The col­lab­o­ra­tion will fo­cus on GPCR drugs in the im­munol­o­gy, gas­troen­terol­o­gy and im­muno-on­col­o­gy spaces, as well as oth­er dis­or­ders with im­muno­pro­tec­tive or im­munopath­o­gen­ic mech­a­nisms, the com­pa­nies said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER